Table 1

Patient characteristics

ParameterMutation group, no. (%)
P
Mutation (N = 86)No mutation (N = 83)
Median age, y (range)  52 (17-80) 48 (21-94) .311 
Prior interferon-α  57 (66) 42 (51) .060 
Stage at imatinib therapy CP 68 (79) 64 (77) .530 
 AP 15 (17) 13 (16)  
 BP 3 (4) 6 (7)  
Best response to imatinib CHR 43 (50) 35 (42) .379 
 MCyR 33 (38) 34 (41) .881 
 CCyR 22 (26) 26 (31) .562 
Median duration of response to imatinib therapy, mo (range)  25 (2-68) 29 (3-69) .20 
Mutation at imatinib failure Low IC50 42 (49)   
 Intermediate IC50 25 (29)   
 High IC50 9 (10)   
 Unknown IC50 10 (12) NA NA 
Stage at TKI switch CP 30 (35) 29 (35) .150 
 AP 41 (48) 30 (36)  
 BP 15 (17) 24 (29)  
Second TKI Dasatinib 41 (48) 40 (48) .928 
 Nilotinib 45 (52) 43 (52)  
Median follow-up from second TKI switch, mo (range)  23 (3-38) 22 (3-36) .861 
ParameterMutation group, no. (%)
P
Mutation (N = 86)No mutation (N = 83)
Median age, y (range)  52 (17-80) 48 (21-94) .311 
Prior interferon-α  57 (66) 42 (51) .060 
Stage at imatinib therapy CP 68 (79) 64 (77) .530 
 AP 15 (17) 13 (16)  
 BP 3 (4) 6 (7)  
Best response to imatinib CHR 43 (50) 35 (42) .379 
 MCyR 33 (38) 34 (41) .881 
 CCyR 22 (26) 26 (31) .562 
Median duration of response to imatinib therapy, mo (range)  25 (2-68) 29 (3-69) .20 
Mutation at imatinib failure Low IC50 42 (49)   
 Intermediate IC50 25 (29)   
 High IC50 9 (10)   
 Unknown IC50 10 (12) NA NA 
Stage at TKI switch CP 30 (35) 29 (35) .150 
 AP 41 (48) 30 (36)  
 BP 15 (17) 24 (29)  
Second TKI Dasatinib 41 (48) 40 (48) .928 
 Nilotinib 45 (52) 43 (52)  
Median follow-up from second TKI switch, mo (range)  23 (3-38) 22 (3-36) .861 

NA indicates not applicable.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal